Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease
World-first MND drug trial offers hope to those living with the disorder
Sydney Alzheimer’s Patients Will Be The First to Trial a New Drug
Hope Pill Will Turn Tables on Dementia
In the News August 8, 2024 By Lisa Wachsmuth— If there was a magic pill to slow the progression of Phil Hazel’s Alzheimer’s disease and allow him to forever retain the happy memories he’s made with his wife Jan, he’d happily swallow it. The Sydney retiree may one day get that chance, with a world-first […]
Addressing Root Causes of Brain Disorders with Innovative Therapeutics
Synapse-regenerating drug could reverse decline in Alzheimer’s
FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS
FDA clears investigational new drug application for clinical trial of ALS pill
Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trial
FDA grants IND clearance for Spinogenix’s ALS treatment trial
